{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:04:26Z","timestamp":1792116266555,"version":"4.4.0"},"reference-count":25,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The paradoxical occurrence of psoriasis triggered by Interleukin-17 (IL-17) inhibitors is notable due to its prominent symptoms and the therapeutic dilemma it presents for follow-up care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe cases in our clinic, perform an in-depth literature review, and suggest the most probable mechanisms of action.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>We conducted a literature review on published cases of IL-17 inhibitor-induced psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found 22 articles reporting 30 cases of IL-17 inhibitor-induced paradoxical psoriasis, primarily observed in patients with a previous psoriasis history. Almost 60% of cases showed a change in lesion morphology, with the plaque or pustular type being prevalent. About 73.3% of patients had to discontinue the implicated drug, leading to partial or complete symptom resolution. The mechanism behind this response seemed to involve IL-17 inhibitors downregulating Tumour Necrosis Factor alpha (TNF-\u03b1), subsequently upregulating plasmacytoid dendritic cells and triggering unopposed IFN-alpha (IFN-\u03b1) production.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Limitation<\/jats:title>\n                    <jats:p>Data are confined to case reports and case series.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>More assertive measures are recommended for treating paradoxical psoriasis induced by IL-17 inhibitors than those caused by TNF-\u03b1 inhibitors. Reintroducing an IL-17 inhibitor is not advised, as patients did not show improvement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.25259\/ijdvl_719_2023","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T05:10:51Z","timestamp":1712380251000},"page":"623-631","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Paradoxical psoriasis induced by IL-17 antagonists"],"prefix":"10.25259","volume":"90","author":[{"given":"Yachen","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Dermatology, Tianjin Medical University General Hospital, Anshan Dao, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengling","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Medical University General Hospital, Anshan Dao, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhe","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Medical University General Hospital, Anshan Dao, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suju","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Tianjin Medical University General Hospital, Anshan Dao, Tianjin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"key":"10.25259\/IJDVL_719_2023\/ref-1","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.autrev.2009.10.003","article-title":"Autoimmune diseases induced by biological agents: A double-edged sword?","volume":"9","author":"Ramos-Casals","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.25259\/IJDVL_719_2023\/ref-2","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/jdv.15288","article-title":"Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: A multicentre retrospective study","volume":"33","author":"Deza","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_719_2023\/ref-3","doi-asserted-by":"publisher","first-page":"e000239","DOI":"10.1136\/rmdopen-2015-000239","article-title":"Paradoxical reactions under TNF-\u03b1 blocking agents and other biological agents for chronic immune-mediated diseases: An analytical and comprehensive overview","volume":"2","author":"Toussirot","year":"2016","journal-title":"RMD Open"},{"key":"10.25259\/IJDVL_719_2023\/ref-4","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/ced.13375","article-title":"Paradoxical localized exacerbation of psoriatic eruptions triggered by secukinumab","volume":"43","author":"Hoshina","year":"2018","journal-title":"Clin Exp Dermatol"},{"key":"10.25259\/IJDVL_719_2023\/ref-5","doi-asserted-by":"publisher","first-page":"e12852","DOI":"10.1111\/dth.12852","article-title":"Multiple paradoxical reactions during ixekizumab therapy","volume":"32","author":"Pirro","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.25259\/IJDVL_719_2023\/ref-6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.ad.2017.12.011","article-title":"Paradoxical arthritis due to ixekizumab in a patient with plaque psoriasis","volume":"110","author":"Vidal","year":"2019","journal-title":"Actas Dermosifiliogr"},{"key":"10.25259\/IJDVL_719_2023\/ref-7","doi-asserted-by":"crossref","first-page":"13030\/qt4624n3hj","DOI":"10.5070\/D3254043589","article-title":"Paradoxical reversed plantar involvement during ixekizumab therapy for psoriasis","volume":"25","author":"Mart\u00ednez-Dom\u00e9nech","year":"2019","journal-title":"Dermatol Online J"},{"key":"10.25259\/IJDVL_719_2023\/ref-8","doi-asserted-by":"publisher","first-page":"446","DOI":"10.2340\/00015555-3138","article-title":"A case of ixekizumab-induced psoriasiform eruption","volume":"99","author":"Oiwa","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"10.25259\/IJDVL_719_2023\/ref-9","doi-asserted-by":"publisher","first-page":"336","DOI":"10.12688\/f1000research.18493.1","article-title":"Case report: Paradoxical acrodermatitis of Hallopeau-like eruption following anti-IL-17 therapy","volume":"8","author":"Cicogna","year":"2019","journal-title":"F1000Res"},{"key":"10.25259\/IJDVL_719_2023\/ref-10","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1080\/14712598.2020.1727439","article-title":"Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: A case series and review of the literature","volume":"20","author":"Caldarola","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"10.25259\/IJDVL_719_2023\/ref-11","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/cup.13952","article-title":"Drug-induced psoriasiform alopecia associated with interleukin-17 inhibitor therapy","volume":"48","author":"Tan","year":"2021","journal-title":"J Cutan Pathol"},{"key":"10.25259\/IJDVL_719_2023\/ref-12","doi-asserted-by":"publisher","first-page":"e325","DOI":"10.1111\/1346-8138.14463","article-title":"Brodalumab-induced palmar pustular eruption and joint swelling accompanied by muscle pains in two cases of psoriasis","volume":"45","author":"Takahashi","year":"2018","journal-title":"J Dermatol"},{"key":"10.25259\/IJDVL_719_2023\/ref-13","doi-asserted-by":"publisher","first-page":"e406","DOI":"10.1111\/jdv.15714","article-title":"First emergence of pyoderma gangraenosum, palmoplantar pustulosis and sacroiliitis in a psoriasis patient associated with switching from secukinumab to brodalumab","volume":"33","author":"Sadik","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_719_2023\/ref-14","doi-asserted-by":"publisher","first-page":"e13346","DOI":"10.1111\/dth.13346","article-title":"Unusual relapse in a psoriasis patient receiving secukinumab: Linear psoriasis","volume":"33","author":"Kurtipek","year":"2020","journal-title":"Dermatol Ther"},{"key":"10.25259\/IJDVL_719_2023\/ref-15","doi-asserted-by":"publisher","first-page":"e468","DOI":"10.1111\/1346-8138.15082","article-title":"Palmoplantar pustulosis emerged on a case of generalized pustular psoriasis successfully treated by secukinumab","volume":"46","author":"Honma","year":"2019","journal-title":"J Dermatol"},{"key":"10.25259\/IJDVL_719_2023\/ref-16","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1097\/RHU.0000000000001076","article-title":"Paradoxical pustular psoriasis in a patient with psoriatic arthritis on secukinumab treatment","volume":"26","author":"Abbruzzese","year":"2020","journal-title":"J Clin Rheumatol"},{"key":"10.25259\/IJDVL_719_2023\/ref-17","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1080\/03009742.2019.1594359","article-title":"New onset of psoriasis induced by secukinumab in a patient with ankylosing spondylitis: A case report","volume":"49","author":"Currado","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"10.25259\/IJDVL_719_2023\/ref-18","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1001\/jamadermatol.2017.2826","article-title":"Secukinumab-induced psoriasiform eruption","volume":"153","author":"Sladden","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_719_2023\/ref-19","doi-asserted-by":"publisher","DOI":"10.1111\/dth.12505","article-title":"Anti IL-17 flared psoriasis in a patient on secukinumab","author":"Noell","year":"2017","journal-title":"Dermatol Ther"},{"key":"10.25259\/IJDVL_719_2023\/ref-20","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/ced.13731","article-title":"Secukinumab-induced paradoxical pustular psoriasis","volume":"44","author":"Dogra","year":"2019","journal-title":"Clin Exp Dermatol"},{"key":"10.25259\/IJDVL_719_2023\/ref-21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1684\/ejd.2020.3702","article-title":"Paradoxical palmoplantar pustulosis induced by secukinumab and brodalumab: A report of three cases","volume":"30","author":"M\u00f6ssner","year":"2020","journal-title":"Eur J Dermatol"},{"key":"10.25259\/IJDVL_719_2023\/ref-22","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/ddg.14639","article-title":"Palmoplantar pustulosis under secukinumab in two patients without psoriasis","volume":"20","author":"Penalba-Torres","year":"2022","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.25259\/IJDVL_719_2023\/ref-23","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1111\/1346-8138.14842","article-title":"Effective treatment with guselkumab for psoriatic alopecia as paradoxical reaction","volume":"46","author":"Hosokawa","year":"2019","journal-title":"J Dermatol"},{"key":"10.25259\/IJDVL_719_2023\/ref-24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jdcr.2021.01.014","article-title":"Paradoxical psoriatic arthritis flare with the initiation of brodalumab and guselkumab","volume":"10","author":"Kashlan","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.25259\/IJDVL_719_2023\/ref-25","doi-asserted-by":"publisher","first-page":"511","DOI":"10.23736\/S2784-8671.21.06801-8","article-title":"Paradoxical reaction to brodalumab in a patient affected by psoriasis","volume":"156","author":"Caravello","year":"2021","journal-title":"Ital J Dermatol Venerol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/paradoxical-psoriasis-induced-by-il-17-antagonists\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/paradoxical-psoriasis-induced-by-il-17-antagonists\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T08:26:48Z","timestamp":1724401608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/paradoxical-psoriasis-induced-by-il-17-antagonists\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":25,"alternative-id":["10.25259\/IJDVL_719_2023"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_719_2023","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,2]]},"article-number":"623"}}